| 1 |
An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder |
|
| | N Simple Santi, Sashi Bhusan Biswal, Birendra Narayan Naik, Jyoti Prakash Sahoo, Bhabagrahi Rath | | | Cureus. 2023; | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management |
|
| | Joan R. Winter, Kimberly Curtis, Bo Hu, Anita H. Clayton | | | Expert Opinion on Drug Safety. 2022; | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression |
|
| | Pattath Narayanan Suresh Kumar, Rohith Suresh, Vikas Menon | | | Indian Journal of Psychological Medicine. 2022; : 0253717622 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice |
|
| | Mohit Chauhan, Rebecca Parry, William V Bobo | | | Neuropsychiatric Disease and Treatment. 2022; Volume 18: 1175 | | | [Pubmed] [Google Scholar] [DOI] | | | 5 |
Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic (Review) |
|
| | Mohamed Abdel-Bakky, Elham Amin, Tarek Faris, Ahmed Abdellatif | | | Molecular Medicine Reports. 2021; 24(6) | | | [Pubmed] [Google Scholar] [DOI] | |
|
